Investigating the effectiveness of beta-blocker on hypermetabolic response in adult patients due to acute burns

Phase 3

Recruiting

• Conditions: Condition 1: Acute Burn. Condition 2: Acute Burn. Condition 3: Acute Burn. Condition 4: Acute Burn. Condition 5: Acute Burn. Condition 6: Acute Burn.; Burn of unspecified degree of head, face, and neck, unspecified site; Burn of unspecified degree of trunk, unspecified site; Burn of unspecified degree of shoulder and upper limb, except wrist and hand, unspecified site; Burn of unspecified degree of hand, unspecified site; Burn of unspecified degree of unspecified site of lower limb, except ankle and foot; Burn of unspecified degree of ankle and foot; T20.00; T21.00; T22.00

• Registration Number: IRCT20230301057584N1
• Lead Sponsor: Bandare-abbas University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 26 June 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 90

Inclusion Criteria

Having wounds from 20 to 50% of the total body surface
Consent to participate in data collection
From the age of 18 to the age of 65 and of both sexes
A history of acute burns in the last two days

Exclusion Criteria

Medical conditions against propranolol use
Head injury
History of cardiopulmonary
endocrine and peripheral diseases
Systolic blood pressure less than 90
Heart rate less than 60
Inhalation damage
History of malignancy
History of AIDS
Complexes related to AIDS and HIV
History of IMI (less than the last 6 weeks), tuberculosis, arthritis, cirrhosis, hyperlipidemia, bone or endocrine diseases, autoimmune diseases
Long-term use of corticosteroids or non-steroidal anti-inflammatory drugs
Renal failure defined as creatinine greater than 3
Liver disease defined as bilirubin more than 3
Anoxic brain damage
Patients with asthma and a history of airway narrowing
Respiratory burn
History of joint or bone disease
Peripheral or central nerve damage
Diabetes or taking any medication that affects the autonomic system
Any type of plastering
Skin wound or skin graft
Contraindication to the use of propranolol
Hypersensitivity to propranolol
A history of hyperthyroidism, unless you are using Synthroid or other thyroid hormones
Chronic opioid overdose pre-burn
Receiving propranolol in the past 6 months
Multiple severe allergic reactions
Daily use of methylphenidate or similar stimulants
Presence of hypoxic brain injury that is not expected to lead to full recovery
History of chronic obstructive pulmonary disease and history of medication use including blocking agents (alpha and beta) or other antiarrhythmic drugs and medical conditions requiring glucocorticoid therapy prior to burn injury.

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Blood pressure. Timepoint: At the beginning of the intervention and during the intervention every 3 hours until the end of discharge from the hospital. Method of measurement: Barometer.;Heart rate. Timepoint: At the beginning of the intervention and during the intervention every 3 hours until the end of discharge from the hospital. Method of measurement: patient vital signs monitoring system.;Body temperature. Timepoint: At the beginning of the intervention and during the intervention every 3 hours until the end of discharge from the hospital. Method of measurement: Thermometer.;Blood oxygen. Timepoint: At the beginning of the intervention and during the intervention every 3 hours until the end of discharge from the hospital. Method of measurement: Pulse Oximeter.

Secondary Outcome Measures

Name	Time	Method
Hospitalization in ICU. Timepoint: Before starting the intervention and After completing the intervention. Method of measurement: Count by number of days.;The duration of the patient's recovery during the intervention period. Timepoint: Before starting the intervention and After completing the intervention. Method of measurement: check list.;Mortality. Timepoint: Before starting the intervention and After completing the intervention. Method of measurement: Check list.;TNF-alpha. Timepoint: Before starting the intervention and After completing the intervention. Method of measurement: Examination of cytokine TNF-alpha using ELISA kit.